Browse studies

Find your next paid study

54 recruiting studies matching your filters

Clinical and Patient Reported Outcomes for Individuals with Relapsed/Refractory Multiple Myeloma Treated with Isatuximab: Real-World Insights from Patient Reported, Wearable, and Qualitative Data in the Context of Digital Health Coaching

This descriptive study aims to evaluate the experience of adults with relapsed or refractory multiple myeloma receiving standard of care isatuximab-irfc throug…

Multiple MyelomaRefractory Multiple Myeloma

Estimated

~$10 – $7,500

Pack HealthNCT05053607

Phase 1

A Phase 1, Open-Label, Dose-Finding Study of BMS-986453, Dual Targeting BCMAxGPRC5D Chimeric Antigen Receptor T Cells, in Participants With Relapsed and/or Refractory Multiple Myeloma

The purpose of this study is to assess BMS-986453 in participants with relapsed and/or refractory multiple myeloma (RRMM).

Relapsed and/or Refractory Multiple Myeloma

Estimated

~$10 – $8,750

Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyNCT06153251

Phase 1

A Phase I/II Study of Elotuzumab and Iberdomide and Dexamethasone Post Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

The aim of this research study is to evaluate the efficacy of Elotuzumab and Iberdomide therapy post-Idecabtagene Vicleucel in participants with relapsed and r…

MyelomaMultiple MyelomaRefractory Multiple Myeloma

Estimated

~$10 – $7,500

Omar Nadeem, MDNCT06518551

Observational

Prehabilitation in Patients With Multiple Myeloma Receiving CAR-T Therapy

This clinical trial evaluates whether prehabilitation with aerobic and resistance exercise improves physical fitness and quality of life outcomes in older pati…

Recurrent Multiple MyelomaRefractory Multiple Myeloma

Estimated

~$10 – $6,250

Mayo ClinicNCT07045727

Phase 1

Phase I Study of Vaccination With DC/MM Fusion Cells in Combination With BCMA Directed CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma

This study is to evaluate the safety and effectiveness of dendritic cell DC/MM fusion vaccine in combination with standard of care B-cell maturation antigen (B…

Multiple MyelomaRefractory Multiple MyelomaRelapse Multiple Myeloma

Estimated

~$10 – $7,500

David AviganNCT07377435

Phase 2

A Phase II Study of ISABELA: Isatuximab, Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

The main goal of this phase II study is to evaluate the overall response rate of isatuximab, belantamab mafodotin, pomalidomide, and dexamethasone in relapsed …

Relapsed CancerRefractory Multiple MyelomaMultiple Myeloma

Estimated

~$10 – $6,250

Massachusetts General HospitalNCT05922501